Clinical Trials Browser

Phase 2 × capivasertib × 1 year × Clear all

NCT02523014 2026-03-04

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Phase 2 Recruiting

Meningioma

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT07426822 2026-02-24

SAFE-CAP

Phase 2 Not yet recruiting

Diarrhea, Exanthema

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05593497 2025-04-16

SNARE

Phase 2 Recruiting

Prostatic Neoplasms

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline